As nicotine pouches continue to expand across global markets, policymakers and public health stakeholders are increasingly asking important questions about their safety profile, long-term health implications, and appropriate regulation.

A recent review published in Tobacco Induced Diseases, “Research on the Safety Risk of Oral Nicotine Products and Its Prospects,” contributes to this growing evidence base by examining available research on oral nicotine products, including nicotine pouches. Drawing upon chemical analyses, animal and cell studies, and human research, the review provides one of the most comprehensive assessments to date of what is currently known about the safety profile of modern oral nicotine products and where important evidence gaps remain.

The review’s conclusions are nuanced and consistent with an increasingly emerging scientific picture. Modern tobacco-free nicotine pouches appear to expose users to substantially fewer toxicants than smoking and many traditional oral tobacco products. However, they are not risk-free, and important questions regarding their long-term health effects remain unanswered.

The evidence therefore supports neither complacency nor alarmism. Instead, it points toward a balanced conclusion: nicotine pouches likely occupy a lower-risk position than combustible cigarettes on the risk continuum, but continued scientific investigation and responsible regulation remain essential.

What Makes Nicotine Pouches Different?

Modern nicotine pouches are smoke-free and tobacco-free products that deliver nicotine orally. Unlike cigarettes, they involve no combustion and contain no tobacco leaf. Most products consist primarily of nicotine salts, fillers, water, sweeteners, and flavourings.

This distinction matters because combustion is the primary driver of smoking-related disease. Cigarette smoke contains thousands of chemicals, including numerous carcinogens and toxicants that contribute to cancer, cardiovascular disease, and respiratory illness. By avoiding combustion and tobacco leaf, nicotine pouches generally contain substantially lower levels of harmful and potentially harmful constituents than cigarettes and many conventional smokeless tobacco products.

The review notes that while some products may contain trace levels of compounds such as nitrosamines, metals, or other constituents, their overall toxicant profile is considerably different from products involving combustion or tobacco leaf.

This does not make nicotine pouches harmless. It does, however, suggest that they should not automatically be assumed to carry risks equivalent to combustible smoking.

What Risks Have Researchers Identified?

The review also highlights several areas where evidence points to potential risks that warrant continued attention.

Nicotine remains an addictive and biologically active substance. Nicotine concentrations vary considerably across products, and some high-strength pouches can deliver substantial nicotine doses. Experimental studies have demonstrated measurable short-term effects, including increases in heart rate and blood pressure, particularly when products are used frequently or contain higher nicotine concentrations.

Researchers have also reported local oral effects associated with pouch use. Some users experience gum irritation, dryness, soreness, white lesions, or changes at the site where the pouch is placed. Current studies suggest that these effects may be influenced by the number of pouches used and the duration of use.

However, existing evidence remains limited. Most studies are relatively small, observational in nature, or subject to methodological limitations. Consequently, the long-term significance of these findings remains uncertain.

The Long-Term Question

Perhaps the most important message emerging from the review is the need for continued long-term research.

Nicotine pouches are relatively new products. Unlike cigarettes, which have been studied over many decades, nicotine pouches do not yet have long-duration epidemiological studies examining cardiovascular outcomes, cancer incidence, oral health progression, or other chronic disease endpoints.

This uncertainty should be acknowledged clearly.

Like any relatively new product category, nicotine pouches have not yet been studied over several decades of use. Some long-term effects, particularly relating to oral health and cardiovascular outcomes, remain uncertain and require further investigation.

However, scientific uncertainty should not automatically be interpreted as evidence that nicotine pouches present risks equivalent to smoking.

The absence of long-term data does not justify assuming either zero risk or cigarette-level risk.

Both uncertainty and evidence can coexist. The current evidence indicates substantially lower exposure to many of the toxicants most strongly associated with smoking-related disease, while also supporting continued surveillance and further research into long-term outcomes.

Understanding Absolute Risk and Relative Risk

Much of the debate surrounding nicotine pouches arises because two different concepts are often conflated: absolute risk and relative risk.

In absolute terms, nicotine pouches are not risk-free. They contain nicotine, can cause dependence, may produce short-term physiological effects, and may have long-term consequences that are not yet fully understood.

In relative terms, however, the available evidence suggests that nicotine pouches expose users to substantially fewer harmful constituents than combustible cigarettes and many traditional smokeless tobacco products.

For public health policy, this distinction is critical.

The appropriate comparison for an adult smoker is not between nicotine pouches and complete abstinence. The more relevant question is whether nicotine pouches expose users to fewer harmful substances than continued smoking.

Across multiple reviews and toxicological assessments, the emerging evidence increasingly supports a lower-risk classification relative to combustible smoking, even while acknowledging that the products are not harmless and that uncertainties remain.

Where Could Public Health Benefit Exist?

The potential public health benefit of nicotine pouches arises when they help adults who smoke move away from combustible tobacco products.

This distinction is fundamental.

The potential benefit becomes much less clear if nicotine pouches are used primarily by young people, non-smokers, or individuals who would not otherwise use nicotine products.

For this reason, discussions about harm reduction cannot be separated from discussions about youth protection.

Strong age restrictions, responsible marketing practices, product standards, ingredient disclosure requirements, transparent toxicant reporting, and effective enforcement all remain essential.

Reducing smoking-related disease and preventing youth uptake are complementary public health objectives. Neither should come at the expense of the other.

What Does This Mean for Regulation?

The review reinforces the need for evidence-based and proportionate regulation.

The current evidence does not justify presenting nicotine pouches as harmless products. Equally, the available evidence does not support treating uncertainty as evidence that nicotine pouches pose risks equivalent to cigarettes.

A proportionate approach would recognise meaningful differences in risk while maintaining robust safeguards.

This includes strong age restrictions, high product standards, transparent reporting of ingredients and toxicants, manufacturing controls, responsible marketing practices, and continued investment in longitudinal research.

The challenge for policymakers is not whether uncertainty exists. It does.

The challenge is how to regulate responsibly while scientific understanding continues to evolve.

The emerging evidence suggests that nicotine pouches likely sit well below combustible cigarettes on the risk spectrum while remaining above complete abstinence. As research develops, regulation should remain aligned with evidence, responsive to emerging findings, and proportionate to the risks products are likely to pose.

 

Frequently Asked Questions: What Does the Evidence Say About Nicotine Pouches?

Q: Does lower toxicant exposure mean nicotine pouches are safe?

A: No. Current evidence does not support describing nicotine pouches as risk-free. However, lower toxicant exposure compared with cigarettes and many traditional oral tobacco products suggests that they may occupy a substantially lower position on the risk continuum. Lower risk should not be confused with no risk.

Q: If long-term effects remain uncertain, should nicotine pouches be treated as harmful as cigarettes?

A: Not necessarily. Scientific uncertainty is not the same as evidence of cigarette-level harm. Long-term data over several decades do not yet exist, but current laboratory and toxicological evidence indicates substantially lower exposure to many of the harmful constituents associated with smoking. Continued research is necessary, but uncertainty alone does not justify assuming equivalent risks.

Q: Why do many researchers distinguish between nicotine pouches and cigarettes?

A: The primary driver of smoking-related disease is combustion. Cigarettes generate toxic smoke containing numerous harmful chemicals. Nicotine pouches do not involve combustion or smoke inhalation and therefore present a fundamentally different toxicological profile, even though they are not risk-free.

Q: Could nicotine pouches have a role in reducing smoking-related harm?

A: The potential public health benefit arises when adult smokers who would otherwise continue smoking completely switch to lower-risk, non-combustible alternatives. That potential benefit is significantly reduced if uptake occurs predominantly among young people, non-smokers, or people who would not otherwise use nicotine.

Q: Does acknowledging lower relative risk mean supporting unrestricted access?

A: No. Recognising differences in risk does not imply deregulation. Strong age restrictions, responsible marketing, product standards, ingredient disclosure requirements, transparent toxicant reporting, and ongoing surveillance remain essential components of effective regulation.

Q: What type of regulatory approach does the current evidence support?

A: The emerging evidence supports proportionate and evidence-based regulation. This means acknowledging remaining uncertainties, investing in long-term research, protecting young people and non-users, and ensuring that regulation reflects meaningful differences in toxicant exposure and comparative risk across product categories.

 

Source

https://www.sciencedirect.com/science/article/pii/S2666027X26000265?via%3Dihub